Corium Launches Innovative ADHD Treatment, AZSTARYS

Corium, Inc., a commercial-stage biopharmaceutical company, launched U.S. sales of AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) a treatment for attention deficit hyperactivity disorder (ADHD) symptoms in people aged 6 years and older. It is the first and only product containing SDX, an extended-release oral prodrug of d-MPH. The U.S. Food and Drug Administration (FDA) approved AZSTARYS in March 2021. AZSTARYS is available as a once-daily oral capsule in three doses.

Corium, a wholly-owned portfolio company of Gurnet Point Capital (GPC), will lead the U.S. commercialization of AZSTARYS. Corium will offer programs . . .